Pharmaceutical Oncology Initiative (POI)

Cancer affects all of us. Every year there are over 250,000 new cases in England and around 159,000 deaths in the UK. While cancer care has progressed in recent years, there is still significant room for improvement in patient outcomes and an increasing need for the industry to work in partnership with the National Health Service and other key stakeholders.

The Pharmaceutical Oncology Initiative (POI) believes that UK cancer survival rates should be comparable with the best in Europe. Established in 2005, it has demonstrated the benefits of collaboration by facilitating major strategic projects that enable people to gain better access to cancer services and medicines.

What is the POI?

The POI is a group of ABPI member-pharmaceutical companies that ensure all people with cancer get the services and medicines they need at the right time. This ensures that they have the best possible chance to manage their disease regardless of where they live.

Our strategy for improving cancer care

The POI aims to address the challenges created by the fast-changing environment of cancer care with a strategy that will:

  • identify areas within the treatment pathway where the usage of medicines can be optimised to be more efficient and effective
  • improve the quality, timeliness and use of information to aid decision making for both patients and healthcare professionals
  • optimise the methodology used in Health Technology Assessments through high-quality research

Future information

To find out more about the POI, or read about future initiatives in cancer care, download the POI booklet (PDF, 2.36 MB).

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.